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The chain of events in the development of
itching includes an initial stimulus, activation of
mediators, firing of terminal endings of small
cutaneous pain fibers, transmission of nerve im-
pulses to the somesthetic cortex, and their identi-
fication as an itch sensation. Some of the mechan-
isms involved have been studied recently by
Shelley and Arthur (1) and by Cormia and
Dougherty (2). Itching analogous to the clinical
variety may be produced experimentally by in-
jections of histamine, naturally occurring pro-
teolytic enzymes or their precursors, and by
direct stimulation of small cutaneous pain nerve
endings with the square wave stimulator (3).
Cormia and Dougherty (2) outlined the prob-
able sequence of events in the development of
itching: tissue injury; liberation of tissue, bac-
terial or serum kinases; activation of pro-en-
zymes; action of proteolytie enzyme on protein
substrate; liberation of mediators such as poly-
peptides and histamine; stimulation of nerve
endings subserving itch. They postulated further
that in addition to the possible proteolytic
activity initiated in the blood and in distal sites,
similar activity might occur in skin by activation
of epidermal and leukoprotease. Both Shelley and
Arthur (1) and Cormia and Dougherty (2) were
able to initiate the enzymatic process and pro-
duce delayed itching with bacterial kinases,
trypsin, plasmin, and some plant proteases,
while the latter workers also produced itching
by the intradermal injection of profibrinolysin
and epidermal protease. An attempt to isolate a
leukoprotease from human blood with the Cohn
fractionator was unsucessful owing to contamina-
tion of leukocytes by serum. Further studies to
detect altered proteolytic activity in the blood
in patients with severe pruritic states were
unsuccessful (4a), except in one case of derma-
titis herpetiformis with many bullous lesions (4b).
For reasons previously discussed (1, 2), it seemed
unlikely that proteolytic enzymes would produce
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itching by histamine release alone. Furthermore,
the nature and severity of itching produced by
the intradermal injection of proteolytie enzymes
then available were not strictly comparable in
quality and severity with clinical itch syndromes.
Accordingly, an investigation has been made of
bradykiaia, a potent, naturally occurring poly-
peptide, and of kallikrein, a proteolytic enzyme
acting on a fraction in alpha 2 serum globulins
to produce a bradykinin-like substance (kallidin).
ICallikrein was identified originally in blood
serum by Frey and Kraut (5). It occurs as the
inactive precursor kallikreinogen, and can be ac-
tivated by proteinases such as trypsin or papaia,
by dilution, by heating, and by alteration of pH
(6). When kallikrein, or for that matter trypsin
or fibriaolysin (plasmin), is added to blood serum,
it acts on bradykininogen in the alpha 2 fraction
of globulin to split off bradykinin. Kallikrein or a
proteolytic enzyme with similar properties has
also been found in saliva, pancreas and a number
of other tissues (6). It is similar to the enzyme
renin, which acts only on hypertensinogen in the
alpha 2 globulin fraction to produce hypertensin.
The substrates of both enzymes may be closely
related (6). Bradykinia belongs to the group of
peptids (kinins) which stimulate smooth muscle
and act as vasodilators (7). It is identified by its
contracting action on isolated smooth muscle
and also by its chromographic properties (8).
Bradykinia formation can be inhibited by soy
bean trypsin inhibitor (9). It can be destroyed by
chymotrypsin, probably by certain peptidases,
and by factors present in serum (6).
There has been much speculation but little
definitive knowledge concerning the role of
kallikrein-like enzymes and the polypeptides in
human disease. Polypeptides of the bradykinin
type arc formed in anaphylactic shock and in
other antigin-antibody reactions (9). The brady-
kiain content of subcutaneous perfusates has
been increased manyfold in inflammation experi-
mentally produced by heat or histamine, and
even by hypnosis (10). Apparently, an intact
peripheral nervous system is a prerequisite for
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this reaction to develop. In general, it is not
known whether kallikrein triggers other pro-
teolytie enzyme systems or whether it is formed
as a late development in proteolytie reactions.
The latter seems more likely, as kallikreia is said
to act only on kallidogen and not on other protein
substrates. However, it does react with certain
synthetic substrates (8).
There are but two related studies on the effects
of kallikrein and bradykinin in human skin.
Herxheimer and Sehaeter (11) studied the wheal
and flare produced by the intradermal injection
of bradykinin, kallidin, wasp kinin, kallikrein,
histamine, and serotonin. Large wheals and large
flares were produced by wasp kiain and hista-
mine, moderate wheals and small flares with
bradykinin and kallidin (possibly identical sub-
strates), a large wheal and no flare with kalli-
krein, and no wheal and a moderate flare with
serotonin. No mention was made of the subjec-
tive reactions to these agents.
The second study, by Armstrong, Jepson,
Keele, and Stewart (12), was concerned with a
pain-producing substance in human inflammatory
exudates and in plasma. The substance was re-
covered from a eantharidia blister or from cell-
poor plasma. If the collected fluid was then ac-
tivated by contact with glass, it produced:
delayed pain when apphed to a blister base; pain
when injected intradermally; and contractions of
the rat uterus. The test substance did not produce
itching. Various tests were then performed and
the substance was shown not to be histamine,
potassium, adenosiae triphosphate, acetyleho-
line or serotonin. It was considered identical in
its effects with bradykinin produced by proteo-
lytie action on plasma globulins.
Ijngar (8) has found that intradermal injection
of kallikrein in guinea pigs produces a localized
hemorrhagic reaction. Bradykinin does not elicit
this reaction. Ungar believes that kallikrein may
have actions other than the formation of brady-
kinin (8).
MATERIALS AND METHODS
Kallikrein,5 and human and dog bradykinin
were used. Human and dog bradykinin were pre-
pared from the globulin fraction of serum, pre-
viously heated at 56° C for three hours to destroy
the enzymes which inactivate bradykinin. The
heated globulin was incubated for 30 minutes at
* Kallikrein was supplied by Dr. George Ungar,
U. S. Vitamin Corp., Yonkers, New York.
37° C with trypsin (0.1 mg. per ml. of serum).
Bradykiain was extracted with boiling alcohol
(70% final concentration). After removal of the
insoluble material and evaporation of the alcohol,
the extract was lyophilized. Activity of the prep-
aration on the isolated guinea pig ileum was com-
pared with a standard preparation.
Bradykinin was obtained from the sera of two
subjects, and was found to be of uniform potency.
The dog bradykinin, although equally effective
when tested on guinea pig ileum, was somewhat
less active as a pain and itch stimulus.
All preparations were stored at —4° C until
ready for use. They were then dissolved in buffered
saline (NaH2PO4 0.576 gm., Na2HPO4 2.5 gm.,
NaCl 8.5 gm. and distil]ed water to 1000 ml.).
The solutions were sterilized by passage through
a Seitz filter and kept in a rubber-stoppered sterile
container. Immediately after use, solutions were
frozen and stored at —4° C until again used.
Stored in this fashion the bradykinin solutions
retained full potency for 10 days and the kallikrein
for one month.
All injections were given intradermally with
0.25 cc syringes and 27 gauge needles, on the flexor
surface of the forearms. Except on a few occasions
for test purposes, injections were given into pain
spots to insnre maximum sensory responses. De-
pending on the preparation used, dilutions of
from 1:10 to 1:100,000,000 were employed. A solu-
tion of freshly prepared histamine phosphate,
0.01 cc of a 1:10,000 dilution, was injected in a
few instances to establish a baseline for compari-
son with the test substances. Doses of kallikrein
and bradykinin were generally 0.01 CI. If the re-
sponse to the test substance was minimal or other-
wise unsatisfactory, subsequent doses varied from
0.02 cc to 0.05 cc. Seven of the subjects used for
testing were adult white males with no discernible
skin or systemic disease; one of these (J. D.) was
known from previous testing with various prote-
olytie enzymes to respond with pruritus that was
less than normal. The eighth subject was a 65-
year-old white man with chronic, idiopathic,
scattered pruritus without cutaneous lesions.
All subjects were given a control injection of
0.02 cc of the buffered saline used in these experi-
ments; the only reaction was an infrequent, tran-
sient, minimal bnrning sensation immediately
after injection. When burning pain was a feature
of the cutaneous response, additional test injec-
tions were given at least 6 cm. f rota the initial
site and frequently on the other forearm, because
of the development of a surrounding area of
hyperalgesia.
The exact composition of the enzyme kallikrcin
is unknown, but it is a protein. It is, however,
not known to be allergenic (8), nor did it produce
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local or other allergic responses io the test sub-
jects. There were no untoward reactioos to brady-
kioio, except for ooe instance where a nodule
with surrounding swelling was noted following a
test injection. In this instance, the solution could
not be sterilized owing to technical reasons. This
reaction was presumably infectious in nature,
since the kinins are not proteins and are not po-
tential antigens.
CLINICAL ODSEEYATIONS
The clinical reactions to hradykinin are sum-
marized in Figure 1.
Bradykinin from 2 human subjects and from a
dog were injected intradermally for 56 trials in
7 test subjects. The concentration of injected
solution varied from 1:10 to 1:100,000,000. The
most characteristic subjective response was the
development of a severe burning pain in 41 of
56 trials in 6 of the 7 test subjects. The pain was
uniformly severe with freshly prepared solutions
in dilutions up to 1:100,000. It appeared 2 or 3
seconds after injection and lasted from 2 seconds
up to 2 minutes 30 seconds (average 23 seconds).
It was less severe, mild, or at times absent under
the following conditions: in concentrations of
1 to 100 million; in solutions prepared more than
10 days previously; and when dog bradykinin
was used.
Itching developed in 34 of the 56 trials, in 5 of
the 7 test subjects. It was generally mild, at times
moderate, but never severe. It was more often
wave-like than contiuuous. If initially continuous,
it invariably became wave-like before its termina-
tion. It was never noted until the subsidence of
the immediate burning pain. It appeared in from
3 to 105 seconds after injection, with an average
time of onset of 44 seconds. There was frequently
a time lag between the subsidence of pain and
the development of itching, the longest interval
being 75 seconds. In 2 trials, initial pain was
superseded immediately by burning, which was
likewise followed at once by itching. In a few in-
stances with severe immediate burning pain,
itching was apparently suppressed. However, it
Number Number Immediate H -
of of aurning Iteb Wheal Flare 1yeeç5uhjeets Trials Pain a g sia
7 56 4234 0 46 38
Ftc. I. Summary of cutaneous reactions to hu-
man and dog bradykinin.
was noted on subsequent testing with more
dilute solutions following a less severe immediate
pain reaction. The itching was never prolonged,
lasting from 10 seconds up to 5 minutes, with an
average of 66 seconds.
Definite whealing was not produced by in-
jections of bradykinin. Questionable whealing
was observed after injection of concentrated
solutions (1:10 and 1:50), but was not tested by
preliminary intravenous injection of a solution
of Evans blue dye. It should be recalled that
Herxheimer and Schacter (11) reported moderate
whealing with bradykinin by this technic.
In 46 of 56 trials, bradykinin produced a mild
flare which varied in size hut averaged about 3
cm. in diameter. It was inconspicuous or absent
with high dilutions of bradykinin. Flaring was
noted in from 20 to 40 seconds after injection, at
times preceding and at other times following the
development of itch.
A central area of hypoalgesia, 1 cm., sur-
rounded by a 2 to 4 cm. area of hyperalgesia, was
a feature of the reaction to bradykinin. It was
noted in 38 of 56 trials, and in 32 of the 41 sites
which reacted with immediate burning pain. The
reaction was more pronounced when the initial
pain was severe.
Subject number 7, the patient with chronic
idiopathic pruritus, was of interest in that neither
objective nor subjective reactions were noted
after intradcrmal injections of 0.02 and 0.05 cc of
a 1:100 solution of human bradykinin. The ab-
sence of response in this patient was not unex-
pected. It had been noted previously that older
subj ects often did not develop itching following
an injection of histamine (13), and that some pa-
tients with severe extensive pruritus did not
develop itching after the injection of histamine
or various proteolytic enzymes (2).
Graham, Goodell, and Wolff (14) have stated
that following a painful local stimulus, itch can-
not be produced in the surrounding area of sec-
ondary hyperalgesia. It is true that a painful
stimulus may suppress or temporarily replace
the sensation of itching, but it seemed unlikely
that itching could not he produced in areas of
surrounding hyperalgesia. This point was tested
by injection of a concentrated solution of brady-
kinin, which produced burning pain followed by
itching. After the subsidence of the initial pain
and itching, a similar or a smaller amount of
bradykinin was injected in the area of hyperal-
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gesia 3 cm. from the initial site. In each of 2 trials
in 2 subjeets, burning pain followed by itching
was noted at the site of reinjection. The experi-
ment was then repeated, using 0.01 cc of 1:10,000
dilution of lustamine for the second injection. In
both subjects intense itching developed in 3 sec-
onds.
A feature of the reactions to bradykinin, kal-
likrein, and of other proteolytie enzymes pre-
viously studied (2) has been the development, 5
to 30 minutes after the test injection, of scattered
pruritus of moderate severity. Previously, the
inference was made that enzyme activators, ac-
tivated proteolytic enzymes, and/or the sec-
ondary mediators, had escaped from the test site
into the general circulation, with the subsequent
development of scattered itching. However, this
supposition could not be confirmed by studies of
blood plasmin levels before and after the intra-
dermal injection of crystalline trypsin (4).
Accordingly, an experiment was devised to test
the nature of scattered itching which was noted
nearly always after the intradermal injection of
solutions of bradykinin. The following experiment
was performed on 2 subjects: 1.5 cc of a 1% pro-
caine solution was injected intradermally and
subcutaneously on the flexor surface of the fore-
arm. Following the onset of complete local
anesthesia, a "blind" intradermal injection of
either 0.05 cc of the buffered saline diluent or of
0.05 cc of a 1:50 solution of human bradykinin
was made in the anesthetic area. The alternate
solution was given in the similarly prepared other
forearm following an interval of 1 hour. By
chance, the placebo was given first in both experi-
ments. Both subjects stated that scattered itch-
ing was more pronounced following the first,
than after the second test injection. It would
appear that the scattered itching noted after in-
jection of bradykinin was the result of overcon-
centration on normal skin sensations and sugges-
tion.
The clinical reactions to Kallikrein are sum-
marized in Figure 2.
Number Number Immediate
-
of of Buroiog Itch wheal Flare a(1Subiects Trials Pairs I
5 23 3 18 18 18 7
FIG. 2. Summary of cutaneous reactions to kal-
likrein.
Five subjects were given intradermal injec-
tions of kallikrein on 23 occasions. The dilutions
were 1:1000, 1:100,000, 1:1,000,000 and
1:10,000,000. The amounts injected varied be-
tween 0.01 and 0.05 cc, depending on reactions
to an initial injection. Because of previous testing
with bradykinin, it was anticipated that im-
mediate burning pain would be a feature of the
reaction to kallikrein. Surprisingly, this was not
the case, and in only 3 of 23 trials was any imme-
diate reaction noted. This consisted of mild tran-
sient burning, only slightly more intense than
that previously experienced with buffered saline.
In 2 of these 3 instances, the subject was one who
previously had shown a tendency to react to
various itch stimuli with transient pain and an
elevated itch threshold to histamine and crystal-
line trypsin.
In 18 out of 23 trials, the striking feature of the
subjective reaction to intradermally injected
kallikrein was a severe, intense, burning itch.
It was noted in 4 instances in which the dilution
of kallikrein was 1:1,000,000 or 1 :10,000,000.
it was absent only in 2 subjects injected with
these same dilutions of kallikrein. The time of on-
set after injection varied between 3 and 70 sec-
onds, with an average of 16 seconds. Itching per-
sisted for 1 to 10 minutes depending on solution
concentration, with an average of 4 minutes and
30 seconds. There were interesting variations in
the development of the itching. In some instan-
ces, it began abruptly as an intense burning which
changed to burning itch and finally to pure itch-
ing. In other subjects, the itching began mildly,
then reached a crisis of burning itch, followed
by gradual subsidence. On a few occasions, the
itching had a burning component throughout its
duration.
\Thealing was a feature of the reaction to
kallikrcin (IS of 23 trials) and was absent only
when dilutions of 1:1,000,000 or more were em-
ployed. The wheals were not large, but were
sharply demarcated. With but one exception,
whealing developed after the onset of itching, the
average time of onset being 45 seconds. Mild
flares averaging 2.5 cm. in diameter were noted in
18 of 23 trials; their average time of onset was 00
seconds, and their development invariably fol-
lowed that of the wheal. Kallikrein flares were
much less pronounced than those produced by
bradykinin; they were not seen with higher dilu-
tions. Hypcralgesia following the injection of
PROTEOLYTIC ACTIVITY IN DEVELOPMENT OF PAIN AND ITCHING 25
Agent Average Itrh Theeshotda
Plasmin (Fibri- 1:1000 Dilution
nolysin)
Epidermal Pro-
tease 1:1000 Dilution
Histamine 1:100,000 Dilution
Trypsin 1:100,000 Dilution
Ficia 1:100,000 Dilution
Papain 1:100,000 Dilution
Kallikrein 1:1,000,000 to 1:10,000,000
(greater dilutions not tested)
Bradykinin 1:1,000,000 to 1:100,000,000
* Smallest amount of test substance producing
itch.
FIG. 3. Comparison of histamine, proteases and
bradykinin as itch stimuli.
kallikrein was noted as slight in 7 trials, doubtful
in another 7, aud abseut iu the remaining 9 trials.
Its development would seem to require a reason-
ably intense preceding pain seusation (14).
Because relatively dilute solutions of brady-
kinin produce severe pain and comparable solu-
tious of kalikrcin produce severe burning itch, a
comparison has been made in normal subjects of
itch thresholds to histamine, kallikrein, other
protcolytic enzymes, and bradykinin. A summary
of these results is presented in Figure 3.
The data presented in Figure 3 are not strictly
comparable; histamine and trypsin are pure sub-
stances, while the remaining proteascs and brady-
kinin contain a variable admixture of adventitious
material. Presumably, the methods of prepara-
tion of some proteases are superior to those for
others.
The itch produced by kallikrein was more in-
tense than that noted with any of the other prepa-
rations, including histamine, even when great
dilutions were employed. Bradykinin also pro-
duced itching in high dilutions, but the sensa-
tion was mild and transient.
DISCUSSION
Two facts of great interest have emerged as a
result of the present investigation. First, the
finding of Armstrong and his associates (12) that
bradykinin is one of the natural tissue mediators
for pain has been confirmed. This pain has a
definite burning component and is presumably
carried on the slow small pain fibers, as is the
sensation of itching (3). Itching, while mild and
transient, has been produced regularly by brady-
kinin, even in great dilution. It is difficult to
reconcile these fiudings with those of the Arm-
strong group until it is recalled that in their ex-
periments bradykinin was applied directly to the
base of an open cantharidcs bulla. In this situa-
tion, free pain nerve endings arc exposed and
presumably traumatized by the cantharidin. A
mixed pain and itch stimulus would give rise
mainly if not exclusively to a sensation of pain,
the milder itch component in the stimulus being
completely suppressed. The production of itch-
ing by bradykinin has an added significance; it
confirms the previous statements by Shelley and
Arthur (1) and the authors (2) that itching is
produced by the mediators formed by proteolytic
action.
Bradykinin is said to produce a marked fall in
blood pressure in the experimental animal (8)
and to be one of the mediating agents in ana-
phylactic shock (9). However, in human skin it
gives rises to little, if any, whealing and to only a
mild arteriolar flare.
The second finding which deserves special com-
ment is that intradcrmal injection of kallikrein
produces an intense burning itch followed by
only a small wheal and a minimal arteriolar flare.
The intensity and the severity of the itch pro-
duced by kallikrein are greater than noted with
any other agents, including histamine. Yet it
would seem that secondary histamine liberation
is not a factor in the development of this itch
since it occurs prior to the onset of the vheal and
flare and the wheal and flare are minimal in
character. Furthermore, kallikrein is said to act
solely on kallidinogen to produce kallidin, and
kallidin is considered to be similar if not identical
to bradykinin in its properties. It would appear,
however, that this may not be the case. As Ungar
has shown (8), intradermal injection of kalli-
krcin in the guinea pig gives rise to a cutaneous
hemorrhage, while injection of bradykinin does
not. The diversity of the subjective reactions to
kallikrcin and bradykinin is additional evidence
that kallikrein may split skin proteins and thus
produce a peptid other than bradykinin. This
unknown pcptid may be one of the prime media-
tors of itching in man. Because of the many
modalities by which kallikrcin may be activated
(other proteases, dilution, heating, change in
pH, ctc), it is reasonable to assume that kinases,
epidcrmal protease, and other protcolytic en-
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zymes transported to the skin, may activate a
kallikrein-like substance, thus producing a peptid
which can give rise to severe itching states.
CONCLUSIONS
1. Intradermal injection of bradykinin gives
rise to a severe immediate burning pain.
2. Mild transient itching, usually somewhat
delayed in its appearance, is produced by the
injection of bradykinin.
3. Severe delayed burning itch can be regu-
larly produced by the intradermal injection of
kallikrein.
4. The prime stimulus for severe itching states
may be a peptid related to, but probably not
identical with, bradykinin.
5. Areas of hyperalgesia produced by brady-
kinin react with itching when injected with
bradykinin or small amounts of histamine.
6. Scattered itching following the intradermal
injection of bradykinin (and by inference, of
proteases as well) is probably due to increased
concentration on cutaneous sensations and the
factor of suggestion, rather than to absorption
of pruritogenic stimuli from an initial itching site.
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